Rani Therapeutics presents preclinical data on the RaniPill® capsule at ENDO 2025 regarding oral delivery of a bispecific agonist.
Quiver AI Summary
Rani Therapeutics Holdings, Inc. announced that it will present preclinical data on its RaniPill® capsule at the Endocrine Society’s Annual Meeting (ENDO 2025) in San Francisco from July 12-15, 2025. The presentation, led by Anvesh Dasari, PhD, will focus on the oral delivery of a bispecific GLP-1/GLP-2 receptor agonist (PG-102) via a robotic pill (RT-114) and demonstrate that it achieves bioequivalence to subcutaneous injection in canines. The session is scheduled for July 14, 2025, in a poster presentation format. Rani Therapeutics specializes in technologies for oral delivery of biologics and drugs, seeking to replace traditional injection methods with more convenient oral options through their proprietary RaniPill® platform.
Potential Positives
- Rani Therapeutics will present preclinical data at a significant industry event (ENDO 2025), showcasing the potential of its RaniPill® capsule technology.
- The presentation includes promising results related to the bioequivalence of an innovative oral delivery system for a bispecific GLP-1/GLP-2 receptor agonist, which could enhance the treatment landscape for patients.
- The RaniPill® capsule represents a proprietary and patented platform technology that could replace current methods of drug delivery, highlighting Rani's innovative approach in the biotherapeutics space.
Potential Negatives
- As a clinical-stage company, Rani Therapeutics may face challenges in securing further funding or partnerships until they demonstrate more advanced clinical results.
- The reliance on preclinical data may indicate that the company has not yet achieved significant milestones in the development of their therapies.
- Presenting data at a conference could suggest a lack of substantial, impactful breakthroughs that warrant more significant media or investor attention.
FAQ
What is the RaniPill® capsule?
The RaniPill® capsule is a proprietary technology developed by Rani Therapeutics for oral delivery of biologics and drugs, replacing injections.
When will Rani Therapeutics present at ENDO 2025?
Rani Therapeutics will present at ENDO 2025 on July 14, 2025, from 12:00 PM to 1:30 PM PT.
What data will be presented at the conference?
Preclinical data on a bispecific GLP-1/GLP-2 receptor agonist via the RaniPill® capsule will be presented.
Who is the presenting author for Rani’s abstract?
The presenting author for Rani's abstract is Anvesh Dasari, PhD.
Where can I find more information about Rani Therapeutics?
More information about Rani Therapeutics can be found on their website at ranitherapeutics.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RANI Hedge Fund Activity
We have seen 13 institutional investors add shares of $RANI stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TWO SIGMA INVESTMENTS, LP removed 291,381 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $367,140
- CITADEL ADVISORS LLC removed 118,966 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $149,897
- TWO SIGMA ADVISERS, LP removed 110,163 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $138,805
- VANGUARD GROUP INC added 89,851 shares (+12.7%) to their portfolio in Q1 2025, for an estimated $113,212
- CWA ASSET MANAGEMENT GROUP, LLC added 83,333 shares (+inf%) to their portfolio in Q1 2025, for an estimated $104,999
- FOREFRONT WEALTH PARTNERS, LLC added 65,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $81,900
- UBS GROUP AG added 48,592 shares (+206.6%) to their portfolio in Q1 2025, for an estimated $61,225
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RANI Analyst Ratings
Wall Street analysts have issued reports on $RANI in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Oppenheimer issued a "Outperform" rating on 05/16/2025
- HC Wainwright & Co. issued a "Buy" rating on 04/03/2025
- Canaccord Genuity issued a "Buy" rating on 02/26/2025
To track analyst ratings and price targets for $RANI, check out Quiver Quantitative's $RANI forecast page.
$RANI Price Targets
Multiple analysts have issued price targets for $RANI recently. We have seen 4 analysts offer price targets for $RANI in the last 6 months, with a median target of $9.0.
Here are some recent targets:
- Andreas Argyrides from Oppenheimer set a target price of $4.0 on 05/16/2025
- Mitchell Kapoor from HC Wainwright & Co. set a target price of $9.0 on 04/03/2025
- Edward Nash from Canaccord Genuity set a target price of $9.0 on 02/26/2025
Full Release
SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule at the Endocrine Society’s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA.
Details of the presentations are as follows:
Abstract Title: Oral Delivery of a Bispecific GLP-1/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT-114) Achieves Bioequivalence to Subcutaneous Injection in Canines
Session Type: Poster Presentation
Session Title: Adipose Tissue, Appetite, and Obesity: From Breakthroughs to Real-World Challenges: Navigating Weight Loss, Regain, and Therapeutic Advances II
Session Date & Time: July 14, 2025 from 12:00 PM to 1:30 PM PT
Poster Number: MON-691
Presenting Author: Anvesh Dasari, PhD
The abstract presented at ENDO 2025 is available on the Endocrine Society website .
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit ranitherapeutics.com.
Investor Contact:
Media Contact:
